Corporate Profile
| Company name | AskAt Inc. |
|---|---|
| Locations |
Head Office 2F Dai-Tokai Bldg., 3-22-8 Meieki, Nakamura-ku, Nagoya, Aichi 450-002, Japan |
| Establishment | January 7, 2013 |
| Capital | 282,091,000 yen |
| Board of Directors | Akihiro Furuta Representative Director, President Shinichi Koizumi Director, Vice-President, Chief Scientific Officer Andrew M Saidel External Director Masami Nakane External Director, Audit and Supervisory Committee Hironari Hatsuzawa External Director, Audit and Supervisory Committee Daisuke Nishii External Director, Audit and Supervisory Committee |
| Operating Team | Tatsuya Asai Director, Administration |
History
| January 2013 | Is launched with capital of 1,000,000 yen as a wholly owned subsidiary of RaQualia Inc. Acquires the following compounds as intellectual property: ・EP4 antagonist / AAT-007, AAT-008 ・5-HT4 partial agonist / AAT-009 ・COX-2 inhibitor / AAT-076 President Shinichi Koizumi |
|---|---|
| June 2013 | Acquires management rights from RaQualia Inc. |
| September 2014 | Relocation of head office to Showa-ku, Nagoya |
| March 2015 | Akihiro Furuta becomes president Becomes fully independent of RaQualia |
| June 2015 | Issues new shares to third parties (capital 9,750,000 yen) |
| August 2015 | Issues new shares to third parties (capital 17,000,000 yen) |
| November 2015 | Acquires CB2 agonist intellectual property from RaQualia Inc. Issues new shares to third parties (capital 32,000,000 yen) |
| January 2016 | Concludes license agreement with RMX (Haihe) for AAT-076 and AAT-007 in China. Issues new shares to third parties (capital 37,000,000 yen) |
| March 2016 | Issues new shares to third parties (capital 62,000,000 yen) |
| December 2016 | Concludes license agreement with Ningbo Tai Kang for AAT-007 in China. |
| January 2017 | Aratana Therapeutics (subsidiary of Elanco Animal Health) launches Galliprant® in USA for Canine Osteoarthritis-associated Pain |
| May 2017 | Issues new shares to third parties (capital 87,000,000 yen) |
| December 2017 | Concludes worldwide license agreement (excluding China and Taiwan) with Arrys Therapeutics (subsidiary of Ikena Oncology) for AAT-007 and AAT-008 Transition to a company with board of directors / company auditor |
| February 2018 | Concludes worldwide license agreement with Aratana Therapeutics (subsidiary of Elanco Animal Health) for AAT-008 in animal health |
| March 2018 | Transition to a company with audit and supervisory committee |
| August 2018 | Relocation of head office to Nakamura-ku, Nagoya |
| September 2018 | RMX(Haihe) initiates Clinical Study of EP4 Antagonist of AAT-007 in the People's Republic of China |
| October 2018 | Arrys Therapeutivs (currently Ikena Oncology), initiates CRC Clinical Study with AAT-007 and Pembrolizumab |
| December 2018 | Arrys Therapeutivs (currently Ikena Oncology), initiates Phase 1b/2 Clinical Studies of AAT-007 in Collaboration with Merck |
| April 2019 | Elanco Animal Health launches Galliprant® in EU for Canine Osteoarthritis-associated Pain |
| June 2019 | Ningbo NewBay Medical Technology Co., Ltd. initiates Clinical Study of EP4 Antagonist AAT-007 in Oncology in the People's Republic of China |
| September 2019 | Concludes license agreement with Oxford Cannabinoid Technologies for AAT-730 in worldwide except Japan |
| October 2019 | RMX (Haihe) initiates Clinical Study of COX-2 Inhibitor AAT-076 for Pain Therapy in the People's Republic of China |
| October 2020 | Issues new shares to third parties (capital 237,091,500 yen) |
| November 2020 | Issues new shares to third parties (capital 267,081,850 yen) |
| March 2021 | Issues new shares to third parties (capital 282,091,000 yen) |
